Table 2.
Prognostic factors in univariate analysis
| Characteristic | Intrathoracic-PFS |
PFS |
OS |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Median (mo) | 1 yr (%) | p-value | Median (mo) | 1 yr (%) | p-value | Median (mo) | 1 yr (%) | p-value | |
| Age (yr) | 0.728 | 0.824 | 0.850 | ||||||
| ≤65 | 5.4 | 32.1 | 2.0 | 13.5 | 6.5 | 29.6 | |||
| >65 | 4.1 | 27.8 | 2.5 | 10.3 | 6.7 | 24.6 | |||
| Sex | 0.083 | 0.199 | 0.152 | ||||||
| Male | 3.7 | 26.7 | 2.0 | 9.9 | 5.6 | 24.6 | |||
| Female | 6.3 | 47.5 | 4.1 | 23.1 | 10.4 | 43.3 | |||
| ECOG performance status | 0.673 | 0.827 | 0.056 | ||||||
| 0–1 | 4.1 | 29.7 | 2.0 | 13.2 | 7.0 | 35.7 | |||
| ≥2 | 6.3 | 30.9 | 2.0 | 10.2 | 4.4 | 8.7 | |||
| Smoking | 0.057 | 0.187 | 0.046 | ||||||
| No | - | 51.4 | 2.7 | 25.0 | 8.0 | 50.0 | |||
| Yes | 3.7 | 24.1 | 2.0 | 8.8 | 5.7 | 24.0 | |||
| Extrathoracic lesion | 0.397 | 0.736 | 0.957 | ||||||
| No | 5.4 | 24.7 | 2.5 | 14.8 | 7.6 | 30.6 | |||
| Yes | 4.1 | 33.4 | 2.0 | 10.4 | 5.7 | 25.9 | |||
| Extrathoracic lesion in bone | 0.162 | 0.182 | 0.788 | ||||||
| No | 5.4 | 31.2 | 2.0 | 13.0 | 5.8 | 32.7 | |||
| Yes | 2.0 | 32.8 | 1.6 | 10.5 | 4.9 | 12.8 | |||
| Extrathoracic lesion in liver | 0.437 | 0.831 | 0.044 | ||||||
| No | 4.1 | 30.6 | 2.0 | 23.8 | 5.8 | 31.2 | |||
| Yes | 1.5 | 30.0 | 1.3 | 11.6 | 2.7 | 0.0 | |||
| Distant metastasis | 0.748 | 0.631 | 0.403 | ||||||
| Single | 5.4 | 30.1 | 2.0 | 8.7 | 4.9 | 31.8 | |||
| Multiple | 2.0 | 46.8 | 1.9 | 19.5 | 6.5 | 13.3 | |||
| Dose (BED) | 0.004 | 0.004 | 0.006 | ||||||
| ≤50 Gy10 | 2.5 | 20.5 | 1.6 | 9.6 | 6.5 | 12.5 | |||
| >50 Gy10 | 10.6 | 39.3 | 3.0 | 15.9 | 6.9 | 40.8 | |||
| PCI | 0.614 | 0.999 | 0.590 | ||||||
| No | 4.1 | 26.4 | 2.0 | 10.3 | 5.7 | 23.0 | |||
| Yes | 6.5 | 43.8 | 1.8 | 20.0 | 10.4 | 50.0 | |||
| Response to the last chemotherapy | 0.829 | 0.450 | 0.042 | ||||||
| Partial response/stable disease | 3.0 | 25.0 | 2.0 | 9.5 | 13.9 | 53.0 | |||
| Progressive disease | 4.1 | 34.7 | 2.0 | 13.4 | 4.8 | 18.9 | |||
PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; BED, biological effective dose; PCI, prophylactic cranial irradiation.